CHMP gives first opinion on paediatric extension
This article was originally published in Scrip
For the first time, the CHMPhas recommended EU centralised approval for a paediatric line extension of a drug that was previously approved only at member state level. The committee has issued a positive opinion on a paediatric line extension of Merck Sharp & Dohme's antihypertensive Cozaar (losartan).
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.